Validating the cytoprotective mechanism of Survivin and other IAPs has become a priority because of the dramatic exploitation of this pathway by human tumors and its frequent association with unfavorable disease outcomes, and the recent identification of molecular antagonists of Survivin that are approaching clinical testing in cancer patients [20–22]. This evidence concerns the gene BIRC5 and cancer.